Nothing Special   »   [go: up one dir, main page]

Caruso et al., 2001 - Google Patents

Whole-blood calcineurin activity is not predicted by cyclosporine blood concentration in renal transplant recipients

Caruso et al., 2001

View PDF
Document ID
11527922737372571285
Author
Caruso R
Perico N
Cattaneo D
Piccinini G
Bonazzola S
Remuzzi G
Gaspari F
Publication year
Publication venue
Clinical chemistry

External Links

Snippet

Background: In transplant patients, current cyclosporine (CsA) dose monitoring with classic pharmacokinetics has demonstrated limitations. Evaluation of the activity of calcineurin (CN), the serine-threonine phosphatase enzyme target of CsA, has been proposed as a reliable …
Continue reading at citeseerx.ist.psu.edu (PDF) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)

Similar Documents

Publication Publication Date Title
Caruso et al. Whole-blood calcineurin activity is not predicted by cyclosporine blood concentration in renal transplant recipients
Armstrong et al. New developments in the immunosuppressive drug monitoring of cyclosporine, tacrolimus, and azathioprine
Millan et al. Pharmacodynamic approach to immunosuppressive therapies using calcineurin inhibitors and mycophenolate mofetil
Yatscoff et al. Pharmacodynamic monitoring of immunosuppressive drugs
Siekierka et al. FK-506 and cyclosporin A: immunosuppressive mechanism of action and beyond
Boleslawski et al. Defective inhibition of peripheral CD8+ T cell IL-2 production by anti-calcineurin drugs during acute liver allograft rejection
Arévalo‐Rodríguez et al. Cyclophilin A and Ess1 interact with and regulate silencing by the Sin3–Rpd3 histone deacetylase
Kung et al. Tissue distribution of calcineurin and its sensitivity to inhibition by cyclosporine
Kiani et al. Manipulating immune responses with immunosuppressive agents that target NFAT
Hemenway et al. Calcineurin: structure, function, and inhibition
Liu FK506 and ciclosporin: molecular probes for studying intracellular signal transduction
Rodríguez et al. A conserved docking surface on calcineurin mediates interaction with substrates and immunosuppressants
Stein et al. Inhibition of stimulated interleukin-2 production in whole blood: a practical measure of cyclosporine effect
Kung et al. IMMUNOPHILINS MAY LIMIT CALCINEURIN INHIBITION BY CYCLOSPORINE AND TACROLIMUS AT HIGH DRUG CONCENTRATIONS1
Capron et al. Intra-cellular immunosuppressive drugs monitoring: A step forward towards better therapeutic efficacy after organ transplantation?
van Rossum et al. Pharmacodynamic monitoring of calcineurin inhibition therapy: principles, performance, and perspectives
Gaymes et al. Cyclolinopeptide A (CLA) mediates its immunosuppressive activity through cyclophilin‐dependent calcineurin inactivation
Yatscoff et al. The monitoring of immunosuppressive drugs: a pharmacodynamic approach
Tannous et al. Mechanism of auto-inhibition and activation of Mec1ATR checkpoint kinase
Yeh et al. The identification and analysis of phosphorylation sites on the Atg1 protein kinase
Ramachandran et al. Antagonistic interactions between the cAMP-dependent protein kinase and Tor signaling pathways modulate cell growth in Saccharomyces cerevisiae
Bremer et al. Expression of IMPDH1 and IMPDH2 after transplantation and initiation of immunosuppression
Blanchet et al. Determination of serine/threonine protein phosphatase type 2B (PP2B) in lymphocytes by HPLC
Koefoed‐Nielsen et al. Blood tacrolimus levels and calcineurin phosphatase activity early after renal transplantation
Hartmann et al. Biochemical monitoring of mTOR inhibitor-based immunosuppression following kidney transplantation: a novel approach for tailored immunosuppressive therapy